These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
192 related articles for article (PubMed ID: 10193429)
1. Alzheimer's beta-amyloid peptides can activate the early components of complement classical pathway in a C1q-independent manner. Bergamaschini L; Canziani S; Bottasso B; Cugno M; Braidotti P; Agostoni A Clin Exp Immunol; 1999 Mar; 115(3):526-33. PubMed ID: 10193429 [TBL] [Abstract][Full Text] [Related]
2. Activation of complement and contact system in Alzheimer's disease. Bergamaschini L; Donarini C; Gobbo G; Parnetti L; Gallai V Mech Ageing Dev; 2001 Nov; 122(16):1971-83. PubMed ID: 11589915 [TBL] [Abstract][Full Text] [Related]
3. Beta-amyloid fibrils activate the C1 complex of complement under physiological conditions: evidence for a binding site for A beta on the C1q globular regions. Tacnet-Delorme P; Chevallier S; Arlaud GJ J Immunol; 2001 Dec; 167(11):6374-81. PubMed ID: 11714802 [TBL] [Abstract][Full Text] [Related]
4. Complement C3 and C4 expression in C1q sufficient and deficient mouse models of Alzheimer's disease. Zhou J; Fonseca MI; Pisalyaput K; Tenner AJ J Neurochem; 2008 Sep; 106(5):2080-92. PubMed ID: 18624920 [TBL] [Abstract][Full Text] [Related]
5. Inhibiting the formation of classical C3-convertase on the Alzheimer's beta-amyloid peptide. Emmerling MR; Spiegel K; Watson MD Immunopharmacology; 1997 Dec; 38(1-2):101-9. PubMed ID: 9476121 [TBL] [Abstract][Full Text] [Related]
6. beta-Amyloid activates complement by binding to a specific region of the collagen-like domain of the C1q A chain. Jiang H; Burdick D; Glabe CG; Cotman CW; Tenner AJ J Immunol; 1994 May; 152(10):5050-9. PubMed ID: 8176223 [TBL] [Abstract][Full Text] [Related]
7. Cytokines associated with amyloid plaques in Alzheimer's disease brain stimulate human glial and neuronal cell cultures to secrete early complement proteins, but not C1-inhibitor. Veerhuis R; Janssen I; De Groot CJ; Van Muiswinkel FL; Hack CE; Eikelenboom P Exp Neurol; 1999 Nov; 160(1):289-99. PubMed ID: 10630213 [TBL] [Abstract][Full Text] [Related]
8. Charge-based binding of complement component C1q to the Alzheimer amyloid beta-peptide. Webster S; Bonnell B; Rogers J Am J Pathol; 1997 May; 150(5):1531-6. PubMed ID: 9137079 [TBL] [Abstract][Full Text] [Related]
9. Complexes between C1q and C3 or C4: novel and specific markers for classical complement pathway activation. Wouters D; Wiessenberg HD; Hart M; Bruins P; Voskuyl A; Daha MR; Hack CE J Immunol Methods; 2005 Mar; 298(1-2):35-45. PubMed ID: 15847795 [TBL] [Abstract][Full Text] [Related]
10. Complement activation and beta-amyloid-mediated neurotoxicity in Alzheimer's disease. Rogers J; Schultz J; Brachova L; Lue LF; Webster S; Bradt B; Cooper NR; Moss DE Res Immunol; 1992; 143(6):624-30. PubMed ID: 1455054 [No Abstract] [Full Text] [Related]
11. Complement activation by beta-amyloid in Alzheimer disease. Rogers J; Cooper NR; Webster S; Schultz J; McGeer PL; Styren SD; Civin WH; Brachova L; Bradt B; Ward P Proc Natl Acad Sci U S A; 1992 Nov; 89(21):10016-20. PubMed ID: 1438191 [TBL] [Abstract][Full Text] [Related]
12. Antibody-independent activation of C1. II. Evidence for two classes of nonimmune activators of the classical pathway of complement. Peitsch MC; Kovacsovics TJ; Tschopp J; Isliker H J Immunol; 1987 Mar; 138(6):1871-6. PubMed ID: 3029223 [TBL] [Abstract][Full Text] [Related]
13. C1q-induced LRP1B and GPR6 proteins expressed early in Alzheimer disease mouse models, are essential for the C1q-mediated protection against amyloid-β neurotoxicity. Benoit ME; Hernandez MX; Dinh ML; Benavente F; Vasquez O; Tenner AJ J Biol Chem; 2013 Jan; 288(1):654-65. PubMed ID: 23150673 [TBL] [Abstract][Full Text] [Related]
14. Early complement components in Alzheimer's disease brains. Veerhuis R; Janssen I; Hack CE; Eikelenboom P Acta Neuropathol; 1996; 91(1):53-60. PubMed ID: 8773146 [TBL] [Abstract][Full Text] [Related]
15. Expression of complement system components during aging and amyloid deposition in APP transgenic mice. Reichwald J; Danner S; Wiederhold KH; Staufenbiel M J Neuroinflammation; 2009 Nov; 6():35. PubMed ID: 19917141 [TBL] [Abstract][Full Text] [Related]
16. Activation of human complement serine-proteinase C1r is down-regulated by a Ca(2+)-dependent intramolecular control that is released in the C1 complex through a signal transmitted by C1q. Thielens NM; Illy C; Bally IM; Arlaud GJ Biochem J; 1994 Jul; 301 ( Pt 2)(Pt 2):509-16. PubMed ID: 8042996 [TBL] [Abstract][Full Text] [Related]
17. Neuronal localization of C1q in preclinical Alzheimer's disease. Fonseca MI; Kawas CH; Troncoso JC; Tenner AJ Neurobiol Dis; 2004 Feb; 15(1):40-6. PubMed ID: 14751769 [TBL] [Abstract][Full Text] [Related]
18. Inflammatory components in human Alzheimer's disease and after active amyloid-β42 immunization. Zotova E; Bharambe V; Cheaveau M; Morgan W; Holmes C; Harris S; Neal JW; Love S; Nicoll JA; Boche D Brain; 2013 Sep; 136(Pt 9):2677-96. PubMed ID: 23943781 [TBL] [Abstract][Full Text] [Related]
19. Induction of complement proteins in a mouse model for cerebral microvascular A beta deposition. Fan R; DeFilippis K; Van Nostrand WE J Neuroinflammation; 2007 Sep; 4():22. PubMed ID: 17877807 [TBL] [Abstract][Full Text] [Related]
20. Aspartate residue 7 in amyloid beta-protein is critical for classical complement pathway activation: implications for Alzheimer's disease pathogenesis. Velazquez P; Cribbs DH; Poulos TL; Tenner AJ Nat Med; 1997 Jan; 3(1):77-9. PubMed ID: 8986745 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]